Valuation: Forte Biosciences, Inc.

Market Cap 897M 784M 724M 668M 1.27B 85.53B 1.29B 8.64B 3.39B 42.13B 3.37B 3.29B 145B P/E 2026 *
-8.94x
P/E 2027 * -8.63x
Enterprise Value 897M 784M 724M 668M 1.27B 85.53B 1.29B 8.64B 3.39B 42.13B 3.37B 3.29B 145B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.86%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+14.43%
1 week+103.99%
Current month+95.93%
1 month+147.53%
3 months+18.65%
6 months+40.37%
Current year+52.68%
1 week 19.95
Extreme 19.95
44.86
1 month 16.6
Extreme 16.6
44.86
Current year 15.51
Extreme 15.51
44.86
1 year 9.1
Extreme 9.1
44.86
3 years 4.11
Extreme 4.11
44.86
5 years 4.11
Extreme 4.11
921.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

Chief Executive Officer

2,598 0.0127%
07-01Fiscal year

Chief Financial Officer

884 0.0043%
06-16Free

Chief Financial Officer

22,000 0.1074%
Change 5-day change 1-year change 3-year change Capi.($)
+14.95%+103.99%+263.47%+64.89% 897M
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%+1.65%+76.90%+95.68% 53.58B
-3.76%+2.07%+17.78%+458.09% 25.63B
-1.91%-2.67%-19.75%-14.90% 23.51B
+2.43%+5.86%+46.56%+0.42% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.74%+10.46%+47.66% - 14.13B
-0.95%+1.60%+24.91%+195.86% 14.35B
Average +0.62%+8.59%+75.19%+137.61% 24.31B
Weighted average by Cap. -1.18%+0.57%+55.57%+136.78%

Financials

2026 *2027 *
Net sales - -
Net income -95.54M -83.57M -77.08M -71.19M -135M -9.11B -137M -921M -362M -4.49B -359M -351M -15.43B -130M -114M -105M -97.19M -184M -12.44B -188M -1.26B -494M -6.13B -490M -479M -21.07B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
11/07/26 US$41.69 +13.60% 1,952,240
09/07/26 US$36.70 +78.33% 4,866,491
08/07/26 US$20.58 -7.51% 590,078
07/07/26 US$22.25 +9.02% 500,708
06/07/26 US$20.41 -2.44% 242,497
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.70USD
Average target price
64.75USD
Spread / Average Target
+76.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock